JPMorgan Chase & Co. Sells 3,767,609 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

JPMorgan Chase & Co. reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 86.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 572,659 shares of the medical equipment provider’s stock after selling 3,767,609 shares during the period. JPMorgan Chase & Co. owned 0.82% of Lantheus worth $62,849,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tidal Investments LLC grew its position in shares of Lantheus by 25.2% in the third quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock valued at $1,934,000 after purchasing an additional 3,547 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the 3rd quarter valued at approximately $25,000. World Investment Advisors LLC acquired a new stake in Lantheus in the 3rd quarter valued at approximately $60,000. Hohimer Wealth Management LLC bought a new position in Lantheus in the 3rd quarter worth approximately $250,000. Finally, Coldstream Capital Management Inc. acquired a new position in shares of Lantheus during the third quarter worth approximately $230,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Up 2.7 %

Shares of LNTH opened at $91.21 on Friday. The stock has a market cap of $6.34 billion, a PE ratio of 15.18 and a beta of 0.45. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a 50 day simple moving average of $91.85 and a 200-day simple moving average of $98.91.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.